ADAPTIMMUNE THERAPEUTICS PLC
Quoted on the US OTC Pink market, Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company developing novel T-cell therapies for the treatment of cancer.
Get an alert when ADAPTIMMUNE THERAPEUTICS PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£19M
USD 25,951,000
-71.5% lowest in 3 filed years
Net assets
£24M
USD 31,969,000
+145.2% vs 2024
Employees
272
-44% lowest in 3 filed years
Profit before tax
-£58M
USD -78,006,000
+57.4% highest in 3 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
9 officer resignations in last 12 months
Multiple officers have left the board recently — see the People section for who.
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £45,127,265 | £0 | £4,434,796 | — | |
| Operating profit | -£117,310,975 | -£136,954,634 | -£54,328,492 | +60.3% | |
| Profit before tax | -£97,925,588 | -£136,936,667 | -£58,396,467 | +57.4% | |
| Net profit | -£87,650,097 | — | — | — | |
| Cash | £107,793,831 | £68,228,028 | £19,427,309 | -71.5% | |
| Total assets less current liabilities | £159,771,672 | £135,923,042 | — | — | |
| Net assets | £32,209,912 | £9,758,946 | — | — | |
| Equity | £32,209,912 | £9,758,946 | £23,932,475 | +145.2% | |
| Average employees | 439 | 486 | 272 | -44% | |
| Wages | £49,496,931 | £55,191,645 | £31,470,280 | -43% | |
| Directors' remuneration | — | £2,539,302 | £1,842,342 | -27.4% |
Figures converted to GBP from USD at 0.749 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Net margin | -194.2% | — | — | |
| Return on capital employed | -73.4% | -100.8% | — | |
| Gearing (liabilities / total assets) | 85.0% | 94.7% | — | |
| Current ratio | 2.86x | 2.88x | 2.04x | |
| Interest cover | -73.99x | -27.84x | -9.99x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- ADAPTIMMUNE THERAPEUTICS PLC 2015-04-01 → present
- ADAPTIMMUNE THERAPEUTICS LIMITED 2014-12-03 → 2015-04-01
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- Grant Thornton UK LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Group structure
- ADAPTIMMUNE THERAPEUTICS PLC · parent
- Adaptimmune Limited 100%
- Adaptimmune LLC 100%
- Adaptimmune B.V. 100%
- CM Intermediate Sub I, Inc. 100%
- CM Intermediate Sub II, Inc. 100%
- TCR2 Therapeutics, Inc. 100%
- Trucs Therapeutics Limited 100%
Significant events
- “On 20 October 2025, the Company announced that it was de-listing from Nasdaq. The Company's shares were subsequently listed on the OTC Pink market.”
- “During the year, the Loan and Security Agreement dated 14 May 2024 with Hercules Capital, Inc. was fully discharged.”
- “On 24 March 2026, the Group agreed to the surrender of the leases held for two properties on Milton Park, Oxfordshire, UK.”
- “In March 2026, the Group agreed to the sale of one of its pre-clinical programmes, ADP-600 (PRAME). The Group received upfront cash consideration of $7 million with a further $5 million expected to be received by end of year 2026, following a technology transfer process.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 17 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| HILL, Christopher James | Secretary | 2025-11-14 | — | — |
| ALLEVA, Lawrence Michael | Director | 2015-03-05 | Oct 1949 | American |
| HILL, Christopher James | Director | 2025-11-14 | Mar 1980 | British |
| MENZEL, Garry Edward, Dr | Director | 2023-06-01 | Aug 1964 | British |
Show 17 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BERTRAND, William Charles | Secretary | 2025-10-01 | 2025-11-14 |
| HENRY, Margaret | Secretary | 2014-12-03 | 2025-09-30 |
| ALLEN, Andrew Roger, Dr | Director | 2023-06-01 | 2025-11-14 |
| BEHBAHANI, Ali, Dr | Director | 2015-02-12 | 2025-11-14 |
| DUNCAN, Barbara Gayle | Director | 2016-06-23 | 2023-06-01 |
| FUREY, John Paul | Director | 2018-07-05 | 2025-11-14 |
| HEGDE, Priti, Dr | Director | 2023-06-01 | 2025-11-14 |
| HEGE, Kristen, Dr | Director | 2023-11-01 | 2025-11-14 |
| KERR, Giles Francis Bertram | Director | 2016-11-01 | 2020-05-29 |
| KNOWLES, Jonathan Kenneth Charles, Dr | Director | 2015-02-12 | 2016-12-31 |
| LAING, Ian Michael | Director | 2015-02-12 | 2016-12-31 |
| MOTT, David Morrell | Director | 2015-02-12 | 2025-11-14 |
| NOBLE, James Julian | Director | 2014-12-03 | 2023-06-01 |
| RAWCLIFFE, Adrian George | Director | 2019-09-01 | 2025-11-14 |
| SIGAL, C Elliott, Dr | Director | 2015-02-12 | 2023-11-01 |
| THOMPSON, Peter Armstrong, Dr | Director | 2015-02-12 | 2018-07-05 |
| ZAKS, Tal Zvi, Dr | Director | 2016-11-14 | 2023-03-31 |
Ownership
Persons with significant control
Filing timeline
Last 20 of 409 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-06-05 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-05-31 | AA | accounts | Accounts with accounts type group | |
| 2026-03-25 | AD01 | address | Change registered office address company with date old address new address | |
| 2026-03-25 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-11-17 | AP03 | officers | Appoint person secretary company with name date | |
| 2025-11-17 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-17 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-17 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-17 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-17 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-17 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-17 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-17 | AP01 | officers | Appoint person director company with name date | |
| 2025-11-17 | TM02 | officers | Termination secretary company with name termination date | |
| 2025-10-03 | AP03 | officers | Appoint person secretary company with name date | |
| 2025-10-02 | TM02 | officers | Termination secretary company with name termination date | |
| 2025-09-18 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-08-01 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-08-01 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2025-06-06 | AA | accounts | Accounts with accounts type group | |
| 2025-06-05 | RESOLUTIONS | resolution | Resolution |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 18
- Capital events
- 0
- Officers appointed
- 2
- Officers resigned
- 9
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.